Search Results

1 - 10 of 17 items :

  • "esophageal adenocarcinoma" x
Clear All

REFERENCES 1. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149-1158. 2. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23:3155-3162. 3. Clemons NJ, Phillips WA, Lord RV. Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther. 2013;14:782-795. 4. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell

REFERENCES 1. SPECHLER SJ. Barrett’s esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis and therapy . Med Clin North Am 2002; 86 (6):1423–45. 2. SHLAHEEN N, RANSOHOFF DF. Gastroesophageal reflux, Barrett esophagus and esophageal cancer: scientific review . Jama. 2002; 287 (15):1972–1981. 3. BARR H. KENDALL C, BAZANT-HEGEMARK F, MOAYYEDI P, SHETTY G, STONE N. Endoscopic screening and surveillance for Barrett’s esophagus clinical implications . Med Gen Med 2006; 8 :88. 4. SHARMA P, FALK GW, WESTON AP, REKER D, JOHNSON M, SAMPLINER RE. Dysplasia

References 1. Jemal A, Bray F, Center MM, et al. Global Cancer statistics.CA Cancer J Clin 2011;61:69-90. 2. Grant KS, DeMeester SR, Kreger V, et al. Effect of Barrett’s esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma. General Thoracic Cardiovascular Surgery 2013;146:31-37. 3. Ballester V, Cruz-Correa M. Endoscopic surveillance of gastrointestinal premalignant lesions: current knowledge and future directions. Curr Opin Gastroenterol 2014;30:477-483. 4. American Gastroenterological Association medical

, Miyamoto S, Sasazuki T, Wake N. Chromosomal deletions and K-ras gene mutations in human endometrial carcinomas. Int J Cancer 1992; 51(1): 47-52. Argüden YT, Hacihananefioĝlu S. Kanser sitogenetiĝi. Klinik Gelisim 2000; 13(8-9-10): 330-335 (in Turkish). Dasgupta S, Chakraborty SB, Roy A, Roychowdhury S, Panda CK. Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients. J Clin Pathol Mol Pathol 2003; 56(5): 263-269. Rao PH, Mathew S, Kelsen DP, Chaganti RSK. Cytogenetics of gastric and esophageal

, MALAGELADA J.R., LANAS A. Association between achalasia and nitric oxide synthase gene polymorphisms. Am J Gastroenterol. 2006; 101 (9):1979-84. 25. FERGUSON H.R., WILD C.P., ANDERSON L.A., MURPHY S.J., JOHNSTON B.T., MURRAY L.J., et al . Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17 (3):727-31. 26. LEE KM., KANG D., PARK S.K., BERNDT S.I., REDING D., CHATTERJEE N., et al . Nitric oxide synthase gene polymorphisms

by dietary myosmine and N '-nitrosonornicotine in rats. Naunyn-Schmiedeberg's Arch Pharmacol 2002;365(Suppl. 1):R140. Vogt S, Fuchs K, Richter E. Genotoxic effects of myosmine in a human esophageal adenocarcinoma cell line. Toxicology 2006;222:71-9. Havla JB, Hill CE, Abdel-Rahman SZ, Richter E. Evaluation of the mutagenic effects of myosmine in human lymphocytes using the HPRT gene mutation assay. Food Chem Toxicol 2009;47:237-41. Bhattacharjee R, Sil PC. The protein fraction of Phyllanthus niruri plays a protective role against acetaminophen induced hepatic

SA, Coppola D, Barthel JS, Kelley ST, Yeatman TJ. Dedifferentiation precedes invasion in the progression from Barrett’s metaplasia to esophageal adenocarcinoma. Clin Cancer Res. 2005;11:2478-85. 27. Santos L, Loo C, Chandraratnam E, Gune S. Anaplastic carcinoma dedifferentiation of solid variant of papillary thyroid carcinoma. Pathology. 2004;36:196-211. 28. Shields CL, Shields JA, Baez K, Cater JR, De Potter P. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer. 1994;73:692-8. 29. Shields CL, Shields JA, Baez KA, Cater J

(2): 136-44. 4. Lerut TE, de Leyn P, Coosemans W, Van Raemdonck D, Cuypers P, Van Cleynenbreughel B. Advanced esophageal carcinoma. World J Surg 1994; 18: 379-87. 5. Waterman TA, Hagen JA, Peters JH, DeMeester SR, Taylor CR, Demeester TR. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann Thorac Surg 2004; 78: 1161-9. 6. Rice TW, Rusch VW, Ishwaran H, Blackstone EH; Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh

reflux-type symptoms. Am J Gastroenterol., 1998;93(10):1816-1822. 8. Ruigomez A., Garcia Rodriguez L.A., Wallander M.A., Johansson S., Graffner H., Dent J. - Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther., 2004;20(7):751-760. 9. Lagergren J., Bergstrom R., Lindgren A., Nyrén O. - Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med., 1999;340(11):825-831. 10. Vaezi M.F. - Sensitivity and specificity of reflux-attributed laryngeal lesions: experimental and clinical

. Nunez C, Bauman A, Egger S et al. Obesity, physical activity and cancer risks: Results from the Cancer, Lifestyle and Evaluation of Risk Study (CLEAR). Cancer Epidemiol. 2017;47:56-63. 32. Singh S, Devanna S, Edakkanambeth Varayil J et al. Physical activity is associated with reduced risk of esophageal cancer, particularly esophageal adenocarcinoma: a systematic review and meta-analysis. BMC Gastroenterology. 2014;14:101. 33. Leitzmann MF, Koebnick C, Freedman ND et al. Physical activity and esophageal and gastric carcinoma in a large prospective study. Am J Prev Med